Business
ADIA Nutrition Announces IRB Approval of All Four Clinical Studies and Registration of Kidney Health Study on ClinicalTrials.gov
Winter Park Autism Study Now Treating Patients; Kidney Study Recruitment to Begin This WeekWinter Park, Florida--(Newsfile Corp. - May 11, 2026) - ADIA Nutrition, Inc. (OTCQB: ADIA), a publicly traded company advancing regenerative medicine through its subsidiary Adia Med of Winter Park, LLC, today announced that all four of its planned clinical studies have received Institutional Review Board (IRB) approval. This milestone enables the continued execution and launch of human trials evaluating...
About this update from Adia Nutrition, Inc.
[{"type":"text","content":"Winter Park Autism Study Now Treating Patients; Kidney Study Recruitment to Begin This Week","length":91,"tagName":"p","attribs":{"class":"nfSubHeading"},"className":""},{"type":"text","content":"Winter Park, Florida--(Newsfile Corp. - May 11, 2026) - ADIA Nutrition, Inc. (OTCQB: ADIA), a publicly traded company advancing regenerative medicine through its subsidiary Adia Med of Winter Park, LLC, today announced that all four of its planned clinical studies have received Institutional Review Board (IRB) approval. This milestone enables the continued execution and launch of human trials evaluating the safety and potential efficacy of the Company's proprietary AdiaVita™ stem cell and exosome therapies.","length":516,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"width":550,"height":401,"url":"https://media.zenfs.com/en/newsfile_64/f532fb3a0f70e0fbe454a0aee0177800"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/yYeb8ZKHXE8elYpoDiKnTg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTcwMA--/https://media.zenfs.com/en/newsfile_64/f532fb3a0f70e0fbe454a0aee0177800","width":550,"height":401},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/1dHgcuy7rGoieGxH_z7jCQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTQ2Nw--/https://media.zenfs.com/en/newsfile_64/f532fb3a0f70e0fbe454a0aee0177800","width":550,"height":401}},"href":"https://images.newsfilecorp.com/files/10520/296894_adia.jpg","hrefExternal":true},{"type":"text","content":"ADIA Nutrition Announces IRB Approval of All Four Clinical Studies and Registration of Kidney Health Study on ClinicalTrials.gov","length":128,"tagName":"p","attribs":{}},{"type":"text","content":"To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10520/296894_adia.jpg","length":118,"tagName":"p","attribs":{}},{"type":"text","content":"The Company's flagship kidney health study, evaluating AdiaVita™ (an umbilical cord blood-derived stem cell and exosome product) combined with glutathione in adults with Stage 2-4 Chronic Kidney Disease, has been officially registered on ClinicalTrials.gov (Study Details | NCT07572890 | Adia Med of Winter Park LLC Chronic Kidney Disease Research Study | ClinicalTrials.gov) and is scheduled to begin recruiting participants this week. The remaini...